- Patients Patients
Reproductive Genetics Testing
Patient Resources
Cost & Billing
- Providers Providers
- Genetic Counseling
- Login Login
- Estimate My Cost
Single-gene carrier screening
In addition to a comprehensive screening test for more than 500 genetic disorders (Inheritest), we also offer screening for specific disorders, such as spinal muscular atrophy (SMA), the most common inherited cause of early childhood mortality.1 With more than 600,000 tested samples, Integrated Genetics has been a leader in the field of SMA research and testing.
Because of the severity and relatively high carrier frequency, there has been increasing interest in carrier screening for SMA in the general prenatal population. “Screening for spinal muscular atrophy should be offered to all women who are considering pregnancy or are currently pregnant.” – ACOG Committee Opinion No. 691, March 2017.
As with most inherited disorders, the risk for being an SMA carrier varies by ethnic background.2
Ethnicity | SMA carrier risk |
---|---|
Caucasian | 1:47 |
Ashkenazi Jewish | 1:67 |
Asian | 1:59 |
Hispanic | 1:68 |
Asian Indian | 1:52 |
African American | 1:72 |
Mixed ethnicities for counseling purposes, consider using the ethnic background with the most conservative risk.
For pregnancies at risk, we also offer prenatal testing to determine whether the baby has the parental mutations, saving patients time and additional testing.
The screening test requires a blood, saliva or a buccal swab sample, and results are typically ready within eight to fourteen days. If a couple has not yet conceived, one partner is usually tested first. If a woman is already pregnant, a couple may opt to be tested at the same time.
In addition to carrier screening, we also offer: serum screening and noninvasive prenatal screening (NIPS, sometimes called NIPT or cell-free DNA), including the pioneering whole-genome NIPS; diagnostic testing that can be used on prenatal and products of conception (POC) samples, as well as pediatric, cord blood or adult samples; and hereditary cancer screening.